Compare · SOLV vs WST
SOLV vs WST
Side-by-side comparison of Solventum Corporation (SOLV) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SOLV and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.35B, about 1.7x SOLV ($13.13B).
- Over the past year, SOLV is up 3.8% and WST is up 51.0% - WST leads by 47.3 points.
- SOLV has been more active in the news (24 items in the past 4 weeks vs 6 for WST).
- SOLV has more recent analyst coverage (19 ratings vs 15 for WST).
- Company
- Solventum Corporation
- West Pharmaceutical Services Inc.
- Price
- $75.85+1.19%
- $315.91-2.11%
- Market cap
- $13.13B
- $22.35B
- 1M return
- +12.60%
- +6.16%
- 1Y return
- +3.76%
- +51.02%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2024
- News (4w)
- 24
- 6
- Recent ratings
- 19
- 15
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest SOLV
- SEC Form SD filed by Solventum Corporation
- Solventum Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Solventum to Participate in the 2026 Jefferies Healthcare Conference
- Solventum Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Alban Carlos
- SEC Form 4 filed by Director Cox Carrie Smith
- SEC Form 4 filed by Director Devore Susan D.
- SEC Form 4 filed by Director Edwards Shirley Ann
- SEC Form 4 filed by Director Eisenberg Glenn A
- SEC Form 4 filed by Director Harris Bernard A Jr
Latest WST
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)
- Director Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)
- Director Lai Goldman Myla was granted 791 shares, increasing direct ownership by 4% to 20,435 units (SEC Form 4)